GANX Stock Overview
Gain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Gain Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.17 |
| 52 Week High | US$5.65 |
| 52 Week Low | US$2.00 |
| Beta | 0.43 |
| 1 Month Change | -21.92% |
| 3 Month Change | -3.06% |
| 1 Year Change | -35.83% |
| 3 Year Change | -74.31% |
| 5 Year Change | n/a |
| Change since IPO | -71.70% |
Recent News & Updates
Recent updates
Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19Gain Therapeutics EPS misses by $0.29
May 10Shareholder Returns
| GANX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | -2.5% | -3.2% |
| 1Y | -35.8% | -3.7% | 19.3% |
Return vs Industry: GANX underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: GANX underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| GANX volatility | |
|---|---|
| GANX Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GANX's share price has been volatile over the past 3 months.
Volatility Over Time: GANX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 31 | Matthias Alder | www.gaintherapeutics.com |
Gain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.
Gain Therapeutics, Inc. Fundamentals Summary
| GANX fundamental statistics | |
|---|---|
| Market cap | US$51.42m |
| Earnings (TTM) | -US$22.27m |
| Revenue (TTM) | US$55.18k |
931.8x
P/S Ratio-2.3x
P/E RatioIs GANX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GANX income statement (TTM) | |
|---|---|
| Revenue | US$55.18k |
| Cost of Revenue | US$11.38m |
| Gross Profit | -US$11.32m |
| Other Expenses | US$10.94m |
| Earnings | -US$22.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.37 |
| Gross Margin | -20,521.64% |
| Net Profit Margin | -40,354.33% |
| Debt/Equity Ratio | 4.5% |
How did GANX perform over the long term?
See historical performance and comparison